Engineered for Ocular Innovation

Key Attributes of the Hydrogel Platform

Our hydrogel technology is a versatile platform employed to create sustained-release therapies that may expand treatment options across multiple ocular conditions.

The hydrogel delivery technology enables creation of sustained release dosage forms of drugs that have been previously approved by the FDA when formulated as drops or injections.

HYDROGEL PLATFORM¹

Low Potential for Inflammation
90% water, biocompatible. No presevatives
Engineered
Steady state or tapered delivery. Release in days or months.
Versatile
Small molecules or large proteins. Usable in several locations within the body.
Convenient
Fully absorbs when drug is delivered. Remains visible for monitoring. Delivered with small-gauge needle or forcepts.
Exclusive
Robust portfolio of patents. Proprietary. Non-standard dosage forms.

Sustained Release Drug Delivery

Our proprietary hydrogel platform is engineered to create soft, biocompatible therapeutics that provide sustained and localized drug delivery.1-4 The goals of localized drug delivery are to facilitate targeted delivery of a drug and minimize systemic exposure.2,5

The hydrogel is a biodegradable polyethylene glycol (PEG)1 network and is preservative free. This hydrogel network is a meshwork that entraps the drug particles.1 When administered, the PEG network hydrates with water, then the drug particles begin to dissolve, diffusing the drug outward from the hydrogel into the surrounding local tissues.1 Following the completion of drug delivery, the hydrogel biodegrades and is cleared from the body.1,6,7

The company’s novel technology can be formulated to provide sustained release from days6,7 to months3,4 depending on the treatment required. The versatile hydrogel platform can be used to deliver both small molecules7 and large proteins at both small and large molecular weights.6,7

Applications of the Hydrogel Technology

Intracanalicular

Intracameral

Intravitreal

REFERENCES: 1. Sawhney AS, et al. US patent 8,409,606 B2. April 2, 2013. 2. Center for Drug Evaluation and Research DEXTENZA approval package (208742Orig1s000). https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/208742Orig1s000Approv.pdf. Accessed April 21, 2021. 3. Boyer DS, et al. Presented at the American Academy of Ophthalmology Annual Meeting; Virtual; November 13-15, 2020. 4. Goldstein MH, et al. Invest Ophthalmol Vis Sci. 2020;61(7):4266. 5. McGrath M, et al. Invest Ophthalmol Vis Sci. 2014;55:472.  6. Tyson SL, et al. J Cataract Refract Surg. 2019;45(2):204-212. 7. Walters T, et al. J Clin Exp Ophthalmol. 2016;7(4):1-11.